Reports Q1 revenue $49.5B, consensus $47.98B. “Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full-year adjusted EPS guidance, supported by greater visibility into the balance of the year. Our actions are driving more consistent performance and position Elevance Health (ELV) for continued improvement over time,” said Gail Boudreaux, President and Chief Executive Officer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $391 from $395 at Jefferies
- ELV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- One in seven enrollees in ACA plans failed to make payments this year, WSJ says
- Elevance Health price target lowered to $375 from $390 at Truist
- Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls